Price is syncing
Reported smart-money activity is still available below.
1 month
+0.4%
price return
Year to date
-2.8%
price return
Big funds
8
hold this stock
News tone
Bullish
19 articles, 7 days
Filed positions and reported activity tied to this stock.
8 funds hold a position.
Real smart money
Recent coverage and its overall tone.
News
Coverage is bullish
14 bullish · 3 neutral · 2 bearish
Tone of tracked coverage
Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint
NeutralJul 24Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab
NeutralJul 24Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial
BearishJul 23Genmab stock trades steadily as investors weigh recent earnings and oncology pipeline momentum
BullishJul 23Phase 3 trial of epcoritamab in relapsed/refractory DLBCL misses primary overall survival endpoint in U.S.
Leans bearishJul 23Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Leans bearishJul 23TD Cowen upgrades Genmab stock rating on drug pipeline confidence
BullishJul 23GMAB Upgraded by TD Cowen -- Price Target Raised to $43.00
BullishJul 22Q1 2026 13F
$5.7M
position
AlphaYou
